Ident. | Authors (with country if any) | Title |
---|
000002 (2021) |
Fabricio Souza Neves [Brésil] | Correlation of the rise and fall in COVID-19 cases with the social isolation index and early outpatient treatment with hydroxychloroquine and chloroquine in the state of Santa Catarina, southern Brazil: A retrospective analysis. |
000027 (2021) |
S. Ortonobes Roig [Espagne] ; N. Soler-Blanco ; I. Torrente Jiménez ; E. Van Den Eynde Otero ; M. Moreno-Ari O ; M. G Mez-Valent | [Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients]. |
000035 (2021) |
L. Anedda [Italie] ; L. Bianchini ; L. Cuzzolin ; G. Finco ; V. Fanos ; M A Marcialis | What if COVID-19 affects the child: which weapons and how to use them. |
000037 (2021) |
Isabel Fambuena-Muedra [Espagne] ; Marta Jiménez-García [Belgique] ; Sarah Hershko [Belgique] ; Irene Altemir-G Mez [Espagne] ; Ana Tobarra-L Pez [Espagne] | What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. |
000046 (2021) |
Paulo Roberto Bignardi [Brésil] ; Carolina Santos Vengrus [Brésil] ; Bruno Matos Aquino [Brésil] ; Alcindo Cerci Neto [Brésil] | Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. |
000050 (2021) |
Isabel S. Hernandes [Brésil] ; Haroldo C. Da Silva [Brésil] ; Hélio F. Dos Santos [Brésil] ; Wagner B. De Almeida [Brésil] | Unveiling the Molecular Structure of Antimalarial Drugs Chloroquine and Hydroxychloroquine in Solution through Analysis of 1H NMR Chemical Shifts. |
000061 (2021) |
Neils Ben Quashie [Ghana] ; Nancy Odurowah Duah-Quashie [Ghana] | Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries. |
000068 (2021) |
Cassandra Doyno [États-Unis] ; Diana M. Sobieraj [États-Unis] ; William L. Baker [États-Unis] | Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. |
000080 (2021) |
Rong Qiu ; Jingwei Li ; Yuxuan Xiao ; Ziyi Gao ; Yihang Weng ; Qiran Zhang ; Chengdi Wang ; Hanlin Gong [République populaire de Chine] ; Weimin Li | The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. |
000118 (2021) |
Carlo Salvarani [Italie] ; Pamela Mancuso [Italie] ; Federica Gradellini [Italie] ; Nilla Viani [Italie] ; Paolo Pandolfi [Italie] ; Massimo Reta [Italie] ; Giuliano Carrozzi [Italie] ; Gilda Sandri [Italie] ; Gianluigi Bajocchi [Italie] ; Elena Galli [Italie] ; Francesco Muratore [Italie] ; Luigi Boiardi [Italie] ; Nicol Pipitone [Italie] ; Giulia Cassone [Italie] ; Stefania Croci [Italie] ; Anna Maria Marata [Italie] ; Massimo Costantini [Italie] ; Paolo Giorgi Rossi [Italie] | Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. |
000138 (2021) |
Katharina Habler [Allemagne] ; Mathias Brügel [Allemagne] ; Daniel Teupser [Allemagne] ; Uwe Liebchen [Allemagne] ; Christina Scharf [Allemagne] ; Ulf Schönermarck [Allemagne] ; Michael Vogeser [Allemagne] ; Michael Paal [Allemagne] | Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum. |
000149 (2021) |
Amir Sarayani [États-Unis] ; Brian Cicali [États-Unis] ; Carl H. Henriksen [États-Unis] ; Joshua D. Brown [États-Unis] | Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. |
000161 (2021) |
Eric Prommer [États-Unis] | Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients. |
000165 (2021) |
Pablo Chicharro [Espagne] ; Pedro Rodríguez-Jiménez [Espagne] ; Ester Mu Oz-Aceituno [Espagne] ; Diego De Argila [Espagne] ; Patricia Mu Oz-Hernández [Espagne] ; Mar Llamas-Velasco [Espagne] | SDRIFE-like rash associated with COVID-19, clinicopathological correlation. |
000175 (2021) |
Okechukwu S. Ogah [Nigeria] ; Ejiroghene M. Umuerri ; Adewole Adebiyi [Nigeria] ; Olanike A. Orimolade [Nigeria] ; Mahmoud U. Sani ; Dike B. Ojji ; Amam C. Mbakwem ; Simon Stewart ; Karen Sliwa | SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications. |
000181 (2021) |
Pravindra Kumar [Inde] ; Ashok Kumar Sah [Inde] ; Greesham Tripathi [Inde] ; Anjali Kashyap [Inde] ; Avantika Tripathi [Inde] ; Rashmi Rao [Inde] ; Prabhu C. Mishra [Inde] ; Koustav Mallick [Inde] ; Amjad Husain [Inde] ; Manoj Kumar Kashyap [Inde] | Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. |
000196 (2021) |
A J J. Lammers [Pays-Bas] ; R M Brohet [Pays-Bas] ; R E P. Theunissen [Pays-Bas] ; C. Koster [Pays-Bas] ; R. Rood [Pays-Bas] ; D W M. Verhagen [Pays-Bas] ; K. Brinkman [Pays-Bas] ; R J Hassing [Pays-Bas] ; A. Dofferhoff [Pays-Bas] ; R. El Moussaoui [Pays-Bas] ; G. Hermanides [Pays-Bas] ; J. Ellerbroek [Pays-Bas] ; N. Bokhizzou [Pays-Bas] ; H. Visser [Pays-Bas] ; M. Van Den Berge [Pays-Bas] ; H. Bax [Pays-Bas] ; D F Postma [Pays-Bas] ; P H P. Groeneveld [Pays-Bas] | Response to correspondence concerning: "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients". |
000199 (2021) |
Francesca Romana Spinelli [Italie] ; Fulvia Ceccarelli [Italie] ; Manuela Di Franco [Italie] ; Fabrizio Conti [Italie] | Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al. |
000200 (2021) |
Marijke Linschoten [Pays-Bas] ; Linda Nab [Pays-Bas] ; Iwan C C. Van Der Horst [Pays-Bas] ; Robert Tieleman [Pays-Bas] ; Folkert W. Asselbergs [Royaume-Uni] | Response to "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients". |
000234 (2021) |
Carlos Diaz-Arocutipa [Pérou] ; Ana Bra Ez-Condorena [Pérou] ; Adrian V. Hernandez [Pérou, États-Unis] | QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. |
000249 (2021) |
Bianza Moise Bakadia ; Feng He [République populaire de Chine] ; Tiatou Souho [Togo] ; Lallepak Lamboni [Togo] ; Muhammad Wajid Ullah [République populaire de Chine] ; Biaou Ode Boni [République populaire de Chine] ; Abeer Ahmed Qaed Ahmed [République populaire de Chine] ; Biampata Mutu Mukole ; Guang Yang [République populaire de Chine] | Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. |